Open AccessSafety and efficacy of MIM D3 ophthalmic solutions in a randomized placebo controlled Phase 2 clinical trial in patients with dry eye
Author(s) -
Karen Meerovitch,
Gail Torkildsen,
John Lonsdale,
Heidi B. Goldfarb,
Teresa Lama,
Garth Cumberlidge,
George W Ousler
Publication year - 2013
Publication title -
clinical ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 56
eISSN - 1177-5483
pISSN - 1177-5467
DOI - 10.2147/opth.s44688
Subject(s) - medicine , placebo , ophthalmology , fluorescein , randomized controlled trial , adverse effect , pathology , alternative medicine , physics , quantum mechanics , fluorescence
To evaluate the safety and efficacy of ophthalmic MIM-D3, a tyrosine kinase TrkA receptor agonist, in patients with dry eye.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom